Want to see HK:8225 full AI Analyst Report?
8225 Stock Chart & Stats
HK$0.14
<HK$0.01(2.58%)
At close: 4:00 PM EST
HK$0.14
<HK$0.01(2.58%)
Day’s Range― - ―
52-Week RangeHK$0.07 - HK$0.20
Previous CloseN/A
Volume40.00K
Average Volume (3M)100.08K
Market Cap
HK$79.63M
Enterprise ValueHK$52.71
Total Cash (Recent Filing)HK$25.16M
Total Debt (Recent Filing)HK$0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding995,351,700
10 Day Avg. Volume4,000
30 Day Avg. Volume100,080
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.36
Price to Sales (P/S)4.69
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetNo reported debt and a zero debt-to-equity ratio reduce interest and refinancing pressure. This conservative financing gives the company greater flexibility to withstand operating weakness and preserve resources for its business, even though losses are eroding equity.
Improved Cash GenerationPositive operating cash flow in 2023–2025 and positive free cash flow in 2024–2025 show that recent cash conversion has improved despite accounting losses. If maintained, this can support ongoing operations without relying as heavily on external funding.
Higher Gross MarginThe improvement in gross margin indicates that the company retained more revenue after direct costs in 2025, potentially strengthening the economics of its core activities. However, the benefit must persist and be matched by cost control because operating expenses still exceed gross profit.
Bears Say
Persistent LossesPersistent losses across 2022–2025 indicate that the business has not yet established a profitable operating model after the stronger 2020–2021 period. A TTM net margin near -52% materially limits internal reinvestment capacity and raises the need for a credible earnings turnaround.
Eroding Equity BaseMaterial equity erosion reflects the cumulative effect of repeated net losses and weak recent returns. A shrinking capital base reduces financial resilience over time, while negative ROE shows that shareholders’ funds are currently producing losses rather than sustainable value creation.
Cash Flow VolatilityAlthough recent cash flow has improved, the roughly 41% free-cash-flow decline in 2025 and prior negative operating cash flow in 2021–2022 show inconsistent cash generation. This volatility makes internally funded growth and long-term planning less dependable.
8225 FAQ
What was China Health Group Inc.’s price range in the past 12 months?
China Health Group Inc. lowest stock price was HK$0.07 and its highest was HK$0.20 in the past 12 months.
What is China Health Group Inc.’s market cap?
China Health Group Inc.’s market cap is HK$79.63M.
When is China Health Group Inc.’s upcoming earnings report date?
China Health Group Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 184 days.
How were China Health Group Inc.’s earnings last quarter?
China Health Group Inc. released its earnings results on Aug 27, 2026. The company reported HK$0.011 earnings per share for the quarter.
Is China Health Group Inc. overvalued?
According to Wall Street analysts China Health Group Inc.’s price is currently Overvalued.
Does China Health Group Inc. pay dividends?
China Health Group Inc. does not currently pay dividends.
What is China Health Group Inc.’s EPS estimate?
China Health Group Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Health Group Inc. have?
China Health Group Inc. has 995,351,700 shares outstanding.
What happened to China Health Group Inc.’s price movement after its last earnings report?
China Health Group Inc. reported an EPS of HK$0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of China Health Group Inc.?
Currently, no hedge funds are holding shares in HK:8225
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Health Group Inc.
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
Biosino Bio-Technology & Science, Inc. Class H
―